NIH Begins HIV Vaccine Trials in North America, South America, Europe

July 15, 2019

(UPI) – The National Institutes of Health announced plans to begin a phase of trials on Monday on a new HIV vaccine. The agency’s National Institute of Allergy and Infectious Diseases, a division of the U.S. Department of Health and Human Services, will start Phase 3 HIV vaccine efficacy trials to assess if a vaccine regimen can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people.